Coeptis Therapeutics Holdings Inc. (NASDAQ COEP)

Coeptis Therapeutics Signs Agreement to Acquire Allogeneic Immuno-Oncology NK Platform in Phase 1 Clinical Trials from Deverra Therapeutics

Proposed transaction would provide Coeptis with two clinical stage assets leveraging NK cell therapies in relapsed or refractory acute myeloid leukemia (AML) and hospitalized respiratory infections, as well as preclinical programs for hematologic and solid tumors.

About admin

Check Also

At Last A Solution To Form 211 Filings For Startup Companies

Last week, the SEC published its final amendments to Exchange Act Rule 15c2-11, which governs the public quoting of securities traded on the OTCQX, OTCQB and Pink markets.